Horizon Pharma (HZNP) Misses Q1 EPS by 4c, Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare
May 9, 2018 7:00 AM EDT-- First-Quarter 2018 Orphan and Rheumatology Net Sales of $172.2 Million Increased 11 Percent;Represented 77 Percent of Total Company Net Sales --
-- First-Quarter 2018 KRYSTEXXA Net Sales Growth of 48 Percent; Increasing Full-Year 2018 Net Sales Growth Guidance to More Than 65 Percent --
-- 50 Percent of Patients Now Enrolled in Teprotumumab Phase 3 Clinical Trial --
-- Establishing New Operating Structure Effective in Second-Quarter 2018, With Two Operating Segments:Â Orphan and Rheumatology; Primary Care --
-- First-Quarter 2018 Net Sales of $223.9 Million;First-Quarter 2018 GAAP Net Loss of $157.3... More
